Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × Hematologic Tests × 30 days × Clear all

Status

Not yet recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Smoking Cessation 2 Lung Neoplasms 2 Pulmonary Disease, Chronic Obstructive 1 Neoplasms 1 Neoplasm, Residual 1 Motor Activity 1 Inflammation 1 Colorectal Neoplasms 1 Cardiovascular Diseases 1

Interventions

blinatumomab 2 Melphalan 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 tislelizumab 1 tisagenlecleucel 1 thymoglobulin 1 pembrolizumab 1 palbociclib 1 nilotinib 1 fludarabine phosphate 1 fludarabine 1 avelumab 1 Whole-Body Irradiation 1 Trastuzumab 1 Sirolimus 1 Rituximab 1 Radiotherapy 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Mycophenolic Acid 1 Monatide (IMS 3015) 1 Levetiracetam 1 Imatinib Mesylate 1 Hydroxychloroquine 1 Hematologic Tests 1 HMPL-013 1 Dasatinib 1 Cytarabine 1 Capecitabine 1 Busulfan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07514715 2026-04-13

RT4

The Lymphoma Academic Research Organisation

Not yet recruiting

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡